BURN 60mg (10-Vial Kit)
- Retatrutide20 mg
- Tirzepatide40 mg
10-vial kit of curated multi-peptide research blend. Batch-specific COA available. For in-vitro laboratory research use only.
Sold strictly as a lyophilized analytical reference standard for in-vitro laboratory research by qualified professionals. Not for use in any living organism. Not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, diagnostic, or health claims are made. No dosing or administration guidance is provided.
Research Overview
A dual metabolic blend — Retatrutide 20 mg paired with Tirzepatide 40 mg in one 60 mg vial.
BURN combines two of the most-studied incretin peptides in current metabolic literature. Retatrutide engages the GLP-1, GIP, and glucagon receptors, while Tirzepatide acts as a dual GLP-1 / GIP agonist. Researchers use combined preparations like this to study overlapping receptor pathways in a single reference material. Published work is early-stage and reflects only what was measured under those study conditions.
- Overlapping GLP-1, GIP, and glucagon receptor activity
- Appetite and satiety signaling pathways
- Glucose handling in research models
- Energy use and substrate metabolism markers
The information above is provided for educational and research reference purposes only. These products are intended for laboratory research use only and are not approved for human consumption. Statements on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Certificate of Analysis
Every batch of BURN 60mg (10-Vial Kit) is independently characterized by HPLC and mass spectrometry. The full COA — including chromatogram, mass spec data, net purity, and net content verification — is available on request for the lot you receive.
- Compound
- BURN 60mg (10-Vial Kit)
- CAS
- N/A
- Method
- HPLC + MS
- Purity
- >99.0% (HPLC)
- Grade
- Research
- Net Content
- 60 mg × 10 vials
